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OBJECTIVE— We compared the renal and systemic vascular (renovascular) response to a
reduction of bioavailable nitric oxide (NO) in type 2 diabetic patients without nephropathy and
of African and Caucasian heritage.
RESEARCH DESIGN AND METHODS— Under euglycemic conditions, renal blood
flow was determined by a constant infusion of paraminohippurate and changes in blood pressure and
renal vascular resistance estimated before and after an infusion of L-Ng-monomethyl-L-arginine.
RESULTS— In the African-heritage group, there was a significant fall in renal blood flow
(46.0 ml/min per 1.73 m2; P 0.05) and rise in systolic blood pressure (10.0 mmHg [95%
CI 2.3–17.9]; P  0.017), which correlated with an increase in renal vascular resistance (r2 
0.77; P  0.004).
CONCLUSIONS— The renal vasoconstrictive response associated with NO synthase inhi-
bition in this study may be of relevance to the observed vulnerability to renal injury in patients
of African heritage.
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The bioavailability of nitric oxide (NO)is central to the regulation of renovas-cular function and is reduced in estab-
l ished hypertension and diabetic
nephropathy (1–3). Studies in rodents sug-
gest that a deficiency of NO is an important
susceptibility factor in the development of
diabetes-related renal injury (4). It is un-
known whether the differences in vulnera-
bility to renal injury in diabetic patients of
African heritage (5) versus Caucasians is re-
lated to NO bioactivity.
RESEARCH DESIGN AND
METHODS— We studied type 2 dia-
betic patients of African and Caucasian
heritage. The patients in the African-
heritage (n  9) and Caucasian-heritage
(n 11) groups had similar distributions
of sex, age, and duration of diabetes (male
75 vs. 70%, P  0.89; mean  SD age
53.3 7.2 vs. 55.2 4.6 years, P 0.50;
and duration 10.3  10.7 vs. 6.8  6.4
years, P  0.37, respectively). Systolic
blood pressure and diastolic blood pres-
sure were 124.4 vs. 122.1 mmHg (P 
0.75) and 77.0 vs. 76.1 mmHg (P 
0.81), respectively. The patients were
naïve to antihypertensive therapy, and
equal numbers in each group received
metformin (n  6) and insulin (n  2).
A1C and urinary albumin were mea-
sured by high-pressure liquid chromatog-
raphy (HA 8-121; Biomen, Berkshire,
U.K.) and immunoturbidimetry, respec-
tively. Serum creatinine was analyzed by a
rate-reaction method. Estimated creati-
nine clearance was calculated from the
Cockcroft-Gault formula. Microalbumin-
uria was excluded on the basis of three
consecutive albumin-to-creatinine ratios
3 mg/mmol in sterile, early-morning
urine samples and a urinary albumin ex-
cretion rate 30 mg/day.
Renal plasma flow (RPF) was mea-
sured by the constant infusion method
(6,7). A bolus dose of 8 mg/kg paramin-
ohippurate (Merck, Sharp & Dohme,
Hoddesdon, U.K.) was given with a 20
mg/min infusion. After a 90-min equili-
bration period, the concentration of the
infusate was multiplied by the infusion
flow rate and divided by the mean of
duplicate plasma samples at this and
subsequent time points. Plasma parami-
nohippurate was assayed after depro-
t e i n i z i ng the s amp l e s w i th 6%
trichloroacetic acid for 10 min at 70°C
and sequentially adding sodium nitrite,
ammonium sul famate , and N-1-
naphthylethylenediamine using a Co-
bas Mira (Roche, Lewes, U.K.).
After initial equilibration, an amino
acid mixture (Vamin; Pharamcia & Up-
john, Milton Keynes, U.K.) was infused
(0.043 ml  kg1  min1). RPF was as-
sessed 80 min later, and then L-NMMA
(Clinalfa, Laufelfingen, Switzerland) was
begun at the nonpressor dose of 20 g 
kg1 min1. Both infusions were contin-
ued for a further 20 min, after which a
final RPF measurement was made.
During the studies, blood pressure
was monitored automatically (Dinamap;
Critikon, Basingstoke, U.K.), and whole
blood was sampled from a venflon in a
hand vein to measure glucose by the oxi-
dase method (One Touch; Lifescan, High
Wycombe, U.K.) every 10 min. Mean ar-
terial pressure (MAP) was calculated as
the diastolic blood pressure plus one-
third of the pulse pressure. Renal blood
flow (RBF) was calculated by dividing the
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RPF by 1 hematocrit and renal vascular
resistance (RVR) by dividing MAP by
RBF. The study was approved by the eth-
ics committee of the Whittington Hospi-
tal National Health Service Trust.
Statistical analysis
Analyses between or within the groups
were performed using SPSS for Windows
(version 10; SPSS, Chicago, IL). Continu-
ous variables were compared with para-
metric or nonparametric tests and
associations tested with Spearman’s rank
correlation test or Pearson’s X2 test ac-
cording to their distribution. Categorical
variables were compared using a 2 test
with continuity correction or Fisher’s ex-
act test. Clearance and RPF measure-
ments were corrected for a body surface
area of 1.73 m2. Data are expressed as
means  SD unless otherwise stated.
RESULTS— Comparative baseline
measurements of RPF and systolic and di-
astolic blood pressures were similar be-
tween the Af r i c an-he r i t age and
Caucasian-heritage groups (RPF 533.7
174.7 vs. 565.3 260.8 ml/min per 1.73
m2, P  0.78; systolic 124.9  23.7 vs.
121.6 12.3 mmHg, P 0.29; and dia-
stolic 77.1  9.5 vs. 76.3  5.7 mmHg,
P  0.81, respectively). There were no
differences in creatinine clearance or me-
dian urinary albumin excretion rate
(93.7 19.9 vs. 98.9 19.5 ml/min per
1.73 m2, P  0.57, and 12.6 [4.1–25.0]
vs. 14.0 [interquartile range 8.5–24.1]
mg/day, P  0.79). Averaged blood glu-
cose was similar (6.7 0.9 vs. 7.4 0.9
mmol/l; P 0.14). A1C was lower in the
African-heritage than in the Caucasian-
heritage group (6.8  0.69 vs. 8.0 
0.94%; P  0.005).
The L-NMMA infusion was associated
with significant changes in systolic blood
pressure in the African-heritage group
(Fig. 1). Relative to the baseline and post–
amino acid measurements, there was a
mean rise of 10.0 mmHg (95% CI 2.3–
17.9; P  0.017) and 7.3 mmHg (1.0–
13.7; P  0.03), respectively, in the
African-heritage group and 4.3 mmHg
(1.8 to 10.4; P 0.23) and 2.4 mmHg
(3.5 to 8.3; P 0.38) in the Caucasian-
heritage group. Final blood pressure was
higher in the African-heritage group
(137.5  9.0 vs. 123.4  14.2 mmHg;
P 0.05) and was associated with a fall in
RBF (46.0 ml/min per 1.73 m2; P 
0.05) and a rise in RVR (from 0.12 0.06
to 0.14  0.04 mmHg ml/min per 1.73
m2; P 0.036). The changes in RVR cor-
related with MAP (r2 0.77; P 0.004).
Renal hemodynamic measures were un-
changed in the Caucasian-heritage group.
CONCLUSIONS— In this study, pa-
tients without hypertension or renal dis-
ease of African heritage had an increased
sensitivity to the renal vasoconstrictive ef-
fect of NO synthase (NOS) inhibition.
These data suggest that a reduction in NO
bioavailability may adversely affect auto-
regulatory processes that could poten-
tially increase vulnerability to renal
damage (8).
We used the amino acid infusion to
optimize renal blood flow and suppress
tubuloglomerular feedback as a contribu-
tor to vasoconstriction. The myogenic
component of the autoregulatory re-
sponse is attenuated by NO (9). There-
fore, the reduction in renal blood flow
that we observed was probably due to an
effect of NOS inhibition on the renovas-
cular smooth muscle.
Figure 1—Data are means SD. A: RPF measured at end of infusion with amino acid and after co-
infusion of amino acid with L-NMMA (L-NMMA) in patients with type 2 diabetes, which fell
significantly in the African-heritage group compared with the Caucasian-heritage group. B: Pro-
file of systolic (SBP) and diastolic (DBP) blood pressure and pulse rate (dashed line) in patients
with type 2 diabetes of African and Caucasian heritage during phases of the hemodynamic studies.
In the African-heritage group, SBP rose significantly in response to L-NMMAandwas higher at the
end of study than that for the Caucasian group.f, African-heritage group;, Caucasian-heritage
group; F, pulse of African-heritage group; E, pulse of Caucasian-heritage group. P 0.05 after
L-NMMA infusion.
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Early in the course of diabetes, NO
production is necessary to forestall a rise
in blood pressure. Hypertension is asso-
ciated with the generation of NO-
quenching free radicals and is a
prerequisite for the development of renal
disease (10–12). Furthermore, the renal
expression of NOS in patients with diabe-
tes is related to the degree of vasculopathy
(13). It could therefore be considered that
upregulation of NO production in pa-
tients of African heritage is related to a
mechanism that opposes an enhanced va-
soconstrictor tendency. Although consis-
tent with experimental studies, these
outcomes require caution before being
generalized. Confirmatory studies in pa-
tients with and without diabetes with
greater power and the evaluation of the
role of vasoconstrictive cytokines, angio-
tensin II, or endothelin-1 as potential
contributors to this hemodynamic re-
sponse are now required.
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